Who TRISENOX is right for
If you have been diagnosed with acute promyelocytic leukemia (APL) that has either returned or
not responded to initial therapy, TRISENOX
® (arsenic trioxide) injection may be an appropriate
treatment option for you.
The U.S. Food and Drug Administration (FDA) approved TRISENOX to treat patients with APL whose
disease has recurred after, or did not respond to, initial therapy. If you are an APL patient
who has experienced relapse, or if your cancer was resistant to your initial therapy, talk to
your doctor about the role that TRISENOX may have in your treatment.
While TRISENOX has been effective for many patients in clinical trials, no one can predict how
you will respond to treatment. Your doctor can give you more information about the likelihood
that TRISENOX will be beneficial to you based on your individual situation. Your doctor can also
tell you what tests will be done to determine if TRISENOX is working for you.
>> Click here for frequently asked questions about therapy with TRISENOX.
Serious adverse events, grade 3 or 4, were common. Those events attributable to TRISENOX in the
Phase 2 study of 40 patients with refractory or relapsed APL included APL differentiation
syndrome (n = 3), hyperleukocytosis (n = 3), QTc interval prolongation (n = 16), atrial
dysrhythmias (n = 2), hyperglycemia (n = 2), and torsades de pointes (n = 1).